The UC Davis Innovation Institute for Food and Health recently hosted scientists, physicians and industry experts to discuss how drugs based on GLP-1 are transforming treatment for obesity, diabetes ...

DALLAS, April 29, 2025 — Glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) agonists — originally developed to treat people with diabetes and obesity — are showing promise for ...

The resulting study, published in the medical journal JAMA Network Open, looked at the health data of 21,790 veterans with type 2 diabetes to compare three different GLP-1 RAs - liraglutide, ...

After a century of progress that cut deaths from cardiovascular disease in half, momentum has stalled. Heart disease and stroke remain the leading causes of death worldwide, mortality rates are ...

A new technology for management of diabetes is cost-effective for patients in the US with type 1 diabetes compared with traditional treatments. Objectives: Advances in diabetes technology have led to ...